4-Phenyl-2-pyrrolidinone
(Synonyms: 4-苯基-2-吡咯烷酮) 目录号 : GC46675A precursor and synthetic intermediate
Cas No.:1198-97-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
4-Phenyl-2-pyrrolidinone is a precursor and synthetic intermediate.1,2 It has been used as a precursor in the synthesis of compounds with anticonvulsant and nootropic activities and is an intermediate in the synthesis of bromodomain-containing protein 4 (BRD4) bromodomain 1 inhibitors.
1.Zhmurenko, L.A., Litvinova, S.A., Mokrov, G.V., et al.Synthesis of 4-phenylpyrrolidone derivatives with anticonvulsant and nootropic activityPharm. Chem. J.53(5)429-435(2019) 2.Hilton-Proctor, J.P., Ilyichova, O., Zheng, Z., et al.Substituted 1-methyl-4-phenylpyrrolidin-2-ones — Fragment-based design of N-methylpyrrolidone-derived bromodomain inhibitorsEur. J. Med. Chem.191112120(2020)
Cas No. | 1198-97-6 | SDF | |
别名 | 4-苯基-2-吡咯烷酮 | ||
Canonical SMILES | O=C1CC(C2=CC=CC=C2)CN1 | ||
分子式 | C10H11NO | 分子量 | 161.2 |
溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 6.2035 mL | 31.0174 mL | 62.0347 mL |
5 mM | 1.2407 mL | 6.2035 mL | 12.4069 mL |
10 mM | 0.6203 mL | 3.1017 mL | 6.2035 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Challenges in GC-MS analysis: Case studies on phenibut and ethylphenidate
Forensic Sci Int 2017 Aug;277:166-178.PMID:28651175DOI:10.1016/j.forsciint.2017.06.002
The challenges associated with drug analysis using GC-MS such as thermal degradation, cyclisation or unwanted side reactions causing potential erroneous identification have become evident in view of the high surge in new drugs available in the market. Two case studies illustrated how alternative methods or modifications to existing techniques can help to circumvent the limitations. In the first case study, phenibut which is a GABA analogue, cyclises to 4-Phenyl-2-pyrrolidinone under thermal conditions. The identification of phenibut was achieved through derivatisation and identification of its TMS derivative. The second case study, thermal degradation was minimised on drugs of interest methylphenidate and ethylphenidate by reducing the injector port temperature to 200°C and maintaining the GC oven temperature at below 190°C in order to prevent thermal degradation of the drugs of interest.